Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danuglipron multiple ascending dose study in Japanese adults with type 2 diabetes
jRCT2031200170Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danuglipron in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Pfizer. Primary endpoints: Number of participants with treatment-emergent treatment-related adverse events, Number of participants with laboratory abnormalities and 2 more. Started Oct 2020; status: completed.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031200170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200170.